Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05608291
Title A Study to Evaluate the Superiority of the Fianlimab and Cemiplimab Combination Compared to Pembrolizumab in Adult and Adolescent Patients With Completely Resected High-Risk Skin Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Age Groups: adult | child | senior
Covered Countries USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS

No variant requirements are available.